Aileron Therapeutics is a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides. Stapled Peptides are a breakthrough solution to address thousands of therapeutically important yet currently undruggable targets. Stapled Peptides have demonstrated their unique ability to penetrate cells throughout the body and modulate protein-protein interactions, critical control points for most human diseases. Aileron is building a robust pipeline of therapeutics for the treatment of cancer, infectious disease, metabolic disease and immune/inflammatory diseases.
